Results 11 to 20 of about 21,131 (181)

NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus [PDF]

Scientific Reports, 2017
Systemic lupus erythematosus (SLE) features a decreased pool of CD4+CD25+Foxp3+ T regulatory (Treg) cells. We had previously observed NKG2D+CD4+ T cell expansion in contrast to a decreased pool of Treg cells in SLE patients, but whether NKG2D+CD4+ T ...
Di Yang, Zhiqiang Tian, Mengjie Zhang, Weibing Yang, Jun Tang, Yuzhang Wu, Bing Ni   +6 more
doaj   +3 more sources

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer [PDF]

Biology, 2023
The family of human NKG2D ligands (NKG2DL) consists of eight stress-induced molecules. Over 80% of human cancers express these ligands on the surface of tumour cells and/or associated stromal elements. In mice, NKG2D deficiency increases susceptibility to some types of cancer, implicating this system in immune surveillance for malignancy.
Ge Tan, Katelyn M. Spillane, John Maher
openaire   +4 more sources

Regulation and gene expression profiling of NKG2D positive human cytomegalovirus-primed CD4+ T-cells. [PDF]

PLoS ONE, 2012
NKG2D is a stimulatory receptor expressed by natural killer (NK) cells, CD8(+) T-cells, and γδ T-cells. NKG2D expression is normally absent from CD4(+) T-cells, however recently a subset of NKG2D(+) CD4(+) T-cells has been found, which is specific for ...
Helle Jensen, Lasse Folkersen, Søren Skov   +2 more
doaj   +1 more source

Leveraging NKG2D Ligands in Immuno-Oncology [PDF]

Frontiers in Immunology, 2021
Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge for the development of efficient treatment options.
Mercedes Beatriz Fuertes, Carolina Inés Domaica, Norberto Walter Zwirner, Norberto Walter Zwirner   +3 more
openaire   +4 more sources

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway

Oncogenesis, 2021
Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao, Haizhen Lin, Dandan Guo, Sijia Cheng, Ying Zhou, Li Zhang, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Lei Tao, Shijia Wu, Mingyao Liu, Wenzheng Jiang   +14 more
doaj   +1 more source

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

OncoImmunology, 2019
Chimeric antigen receptor (CAR) T cell immunotherapies have shown remarkable efficacy in treating multiple types of hematological malignancies but are not sufficiently effective at treating solid tumors. NKG2D is a strong activating receptor for NK cells
Ruocong Zhao, Lin Cheng, Zhiwu Jiang, Xinru Wei, Baiheng Li, Qiting Wu, Suna Wang, Simiao Lin, Youguo Long, Xuchao Zhang, Yilong Wu, Xin Du, Duanqing Pei, Pentao Liu, Yangqiu Li, Shuzhong Cui, Yao Yao, Peng Li   +17 more
doaj   +1 more source

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Frontiers in Immunology, 2020
CAR T cell approaches to effectively target AML and T-ALL without off-tumor effects on healthy myeloid or T cell compartments respectively are an unmet medical need.
Lina Driouk, Joanina K. Gicobi, Yusuke Kamihara, Kayleigh Rutherford, Glenn Dranoff, Jerome Ritz, Jerome Ritz, Susanne H. C. Baumeister, Susanne H. C. Baumeister, Susanne H. C. Baumeister, Susanne H. C. Baumeister   +10 more
doaj   +1 more source

Acute myeloid leukemia and NK cells: two warriors confront each other

OncoImmunology, 2019
Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed ...
Aroa Baragaño Raneros, Carlos López-Larrea, Beatriz Suárez-Álvarez   +2 more
doaj   +1 more source

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy

OncoImmunology, 2017
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and ...
Eric Lazear, Reza Ghasemi, Sarah M. Hein, John Westwick, Dan Watkins, Daved H. Fremont, Alexander Sasha Krupnick   +6 more
doaj   +1 more source

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment

OncoImmunology, 2017
Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy.
Guranda Chitadze, Charlotte Flüh, Elgar Susanne Quabius, Sandra Freitag-Wolf, Christian Peters, Marcus Lettau, Jaydeep Bhat, Daniela Wesch, Hans-Heinrich Oberg, Stefanie Luecke, Ottmar Janssen, Michael Synowitz, Janka Held-Feindt, Dieter Kabelitz   +13 more
doaj   +1 more source